NMRA-215 / Neumora Therap - LARVOL DELTA

Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model (Neumora Press Release) - "NMRA-215 demonstrated class-leading weight loss of up to 19% as a monotherapy with semaglutide-like induction; NMRA-215 demonstrated best-in-class weight loss of up to 26% in combination with semaglutide; Class-leading weight loss driven by best-in-class pharmacology and brain penetration of NMRA-215; Neumora plans to initiate Phase 1 clinical study in the first quarter of 2026."

New P1 trial • Preclinical • Obesity